Anthropic has announced that the Anthropic Long-Term Benefit Trust has appointed Dr. Vas Narasimhan, CEO of Novartis, to Anthropic’s Board of Directors. As a physician-scientist leading a major innovative medicines company, Narasimhan brings extensive experience in navigating highly regulated industries and overseeing the approval of over 35 novel medicines.
Anthropic, a Public Benefit Corporation, utilizes its unique Trust structure to ensure its governance remains aligned with the responsible development of AI for the long-term benefit of humanity. With this appointment, Trust-selected directors now hold a majority on the board for the first time. Daniela Amodei, Co-Founder and President of Anthropic, stated, “Vas brings something rare to our board. He’s overseen the development and approval of more than 35 novel medicines for the benefit of patients around the world in one of the most regulated industries.”
In his new role, Narasimhan will provide guidance as the firm develops consequential technology with potential applications across healthcare and the life sciences. Narasimhan noted, “In healthcare, AI is accelerating solutions to some of the hardest scientific challenges, from deepening our understanding of disease biology to designing better medicines.” His presence on the board, alongside leaders such as Reed Hastings and Jay Kreps, reinforces the organization’s commitment to balancing commercial growth with ethical oversight.